Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 406 to 420 of 1058 results for drug therapy

  1. Prioritisation board decisions 2025

    Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.

  2. Leg ulcer infection: antimicrobial prescribing (NG152)

    This guideline sets out an antimicrobial prescribing strategy for adults with leg ulcer infection. It aims to optimise antibiotic use and reduce antibiotic resistance.

  3. Ustekinumab for treating moderate to severe plaque psoriasis (TA180)

    Evidence-based recommendations on ustekinumab (Stelara) for treating psoriasis in adults.

  4. Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma (TA894)

    Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for relapsed or refractory follicular lymphoma in adults.

  5. Percutaneous mechanical thrombectomy for acute deep vein thrombosis of the leg (HTG516)

    Evidence-based recommendations on percutaneous mechanical thrombectomy for acute deep vein thrombosis of the leg in adults. This involves removing the clot through a catheter inserted into the vein.

  6. Antimicrobial prescribing: eravacycline for complicated intra-abdominal infections in adults (ES40)

    Summary of the evidence on eravacycline for complicated intra-abdominal infections in adults

  7. Headaches in over 12s: diagnosis and management (CG150)

    This guideline covers the diagnosis and management of tension-type headache, migraine (including migraine with aura and menstrual-related migraine), cluster headache and medication overuse headache in young people (aged 12 years and older) and adults. It aims to improve the recognition and management of headaches, with more targeted treatment to improve the quality of life for people with headaches, and to reduce unnecessary investigations.

  8. Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer (TA816)

    Evidence-based recommendations on alpelisib (Piqray) with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally advanced or metastatic breast cancer in adults.

  9. Transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine (HTG643)

    Evidence-based recommendations on transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine in adults. This involves attaching a small device on the forehead to send small electrical currents to the nerves that bring sensation to the upper eyelids, forehead and scalp.

  10. What is the clinical effectiveness and safety of differing doses of lipid-modifying therapy in children with FH?

    clinical effectiveness and safety of differing doses of lipid-modifying therapy in children with FH? Any explanatory notes(if...

  11. Empagliflozin in combination therapy for treating type 2 diabetes (TA336)

    Evidence-based recommendations on empagliflozin (Jardiance) in combination therapy for treating type 2 diabetes.

  12. Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab (ESNM13)

    Summary of the evidence on subcutaneous trastuzumab for HER2-positive breast cancer to inform local NHS planning and decision-making

  13. Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C (TA106)

    Evidence-based recommendations on peginterferon alfa (Pegasys) and ribavirin for people with mild chronic hepatitis C.

  14. Learning disability: identifying and managing mental health problems (QS142)

    This quality standard covers the prevention, assessment and management of mental health problems in people with learning disabilities in all settings (including health, social care, education, and forensic and criminal justice). It also covers family members, carers and care workers.

  15. Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)

    Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and for preventing a further deep vein thrombosis or pulmonary embolism in adults.